ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial
Posted innews Oncology Pathology & Lab Medicine

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial

The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation for ctDNA-positive patients failed to improve recurrence-free survival.
Distinct Genomic Mutation Patterns in Early-Onset Colorectal Cancer: Implications for Clinical Stratification and Precision Medicine
Posted inClinical Updates Gastroenterology news Oncology Pathology & Lab Medicine Specialties

Distinct Genomic Mutation Patterns in Early-Onset Colorectal Cancer: Implications for Clinical Stratification and Precision Medicine

A large international study reveals unique somatic mutation profiles and higher mutational burden in hypermutated early-onset colorectal cancer, highlighting the need for age-specific molecular diagnostics and management strategies.